The PubMed record describes LITESPARK-011, a multicentre, randomised, open-label, controlled phase 3 clinical trial comparing the combination of belzutifan plus lenvatinib against cabozantinib in patients with previously treated advanced renal cell carcinoma (RCC). The citation indicates publication in Lancet (2026 Aug 29;408:808–820; DOI 10.1016/S0140-6736(26)01089-5), with an electronic publication date of Aug 12, 2026.
The information supplied in the source excerpt focuses on bibliographic details, authorship, and collaborating investigators. The supplied PubMed page includes the trial title, lead and collaborating authors, affiliations spanning many countries, and a link to the full-text provider. The excerpt does not include the trial abstract text, methods, numerical results, or conclusions.
From the title and PubMed metadata, the trial is explicitly described as randomised, open-label, and controlled. It is a phase 3 study, indicating a late-stage trial intended to evaluate efficacy and safety in a larger patient population, likely across multiple sites. The precise number and geographic distribution of participating sites are not reported in the provided excerpt beyond the broad international affiliations listed for authors and investigators.
The title identifies the target population as patients with previously treated advanced renal cell carcinoma. No further eligibility criteria, baseline demographic characteristics, prior lines of therapy, histologic subtypes, performance status requirements, or specific inclusion/exclusion criteria are provided in the excerpt. The sample size and patient disposition are not reported in the supplied text.
The comparison in the trial is between the combination of belzutifan plus lenvatinib and cabozantinib. The PubMed excerpt does not specify dosing regimens, schedule, route of administration, duration of treatment, dose modifications, or criteria for treatment discontinuation. Those operational details are not present in the source material provided here.
The article title and metadata do not specify the trial’s primary or secondary endpoints (for example, overall survival, progression-free survival, objective response rate, patient-reported outcomes, or biomarker assessments). No description of radiologic assessment schedules, response criteria (such as RECIST), or safety outcome measures appears in the supplied excerpt.
The excerpt does not provide the planned sample size, power calculations, statistical hypotheses, analysis populations (intent-to-treat, per-protocol), or planned interim analyses. Information on randomisation methods, stratification factors, or statistical models used is not reported in the provided text.
The PubMed excerpt does not include efficacy results, numerical outcomes, treatment effect estimates, confidence intervals, p values, or subgroup analyses. Because the supplied source text lacks the abstract and results sections, no trial outcome data can be summarised here. Any details concerning response rates, survival outcomes, or comparative efficacy between the belzutifan–lenvatinib combination and cabozantinib are not reported in the provided material.
Safety findings, adverse event frequencies and grades, treatment-related toxicities, dose reductions, or treatment discontinuation rates are not included in the excerpt. Therefore, no safety conclusions can be drawn from the supplied PubMed content.
The PubMed record lists many authors and a broad, international set of affiliations. The lead author is Robert J Motzer, and the author list includes multiple academic investigators from North America, Europe, Asia, South America, and Australia. Corporate contributors associated with Merck & Co are also named among authors and collaborators. An extended list of LITESPARK-011 investigators and collaborators is provided in the metadata portion of the PubMed page excerpt.
The citation indicates the full report appears in Lancet. The PubMed entry includes a link to Elsevier Science for full-text access. The DOI is 10.1016/S0140-6736(26)01089-5 and the publication details are Lancet 2026 Aug 29;408(10557):808–820, with an Epub date of Aug 12, 2026.
This rewritten summary is limited to the information present in the supplied PubMed excerpt. Key trial content—methods, eligibility criteria, dosing, sample size, statistical plan, efficacy outcomes, safety data, and authors’ conclusions—are not included in the provided text and therefore are not reported here. For complete trial results and detailed interpretation, readers should consult the full Lancet article and its abstract, full methods, results, tables, and figures.
The PubMed entry includes a full-text link (Elsevier Science/Lancet). To obtain the trial’s complete methods, efficacy and safety data, and authors’ conclusions, access the Lancet article via the DOI or journal website. The PubMed page lists extensive collaborator and affiliation information that may assist in identifying participating centres and investigator contacts.